letrozole has been researched along with Triple Negative Breast Neoplasms in 3 studies
Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al Mamari, N | 1 |
| Son, WY | 1 |
| Pansera, M | 1 |
| Badeghiesh, A | 1 |
| Dahan, MH | 1 |
| Russo, M | 1 |
| Liu, K | 1 |
| Chan, C | 1 |
| Marin, L | 1 |
| Vitagliano, A | 1 |
| Capobianco, G | 1 |
| Dessole, F | 1 |
| Ambrosini, G | 1 |
| Andrisani, A | 1 |
3 other studies available for letrozole and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
IVF stimulation in pregnancy: lessons to be learned with implications for the luteal phase start IVF cycle.
Topics: Female; Fertility Preservation; Humans; Letrozole; Luteal Phase; Oocyte Retrieval; Ovulation Inducti | 2020 |
Suboptimal response to GnRH-agonist trigger during oocyte cryopreservation: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Buserelin; Chorionic Go | 2020 |
Which is the optimal timing for starting chemoprotection with gonadotropin-releasing hormone agonists after oocyte cryopreservation? Reflections on a critical case of ovarian hyperstimulation syndrome.
Topics: Adult; Anticoagulants; Antineoplastic Agents, Hormonal; Ascites; Cryopreservation; Cryoprotective Ag | 2021 |